Biotech Soars on Research Collaboration And License Agreement Release - InvestingChannel

Biotech Soars on Research Collaboration And License Agreement Release

A California-based biotech company is turning heads on Wednesday after it announced that it entered into a research collaboration and license agreement with Astellas Pharma’s Xyphos Biosciences subsidiary.

Shares of Poseida Therapeutics Inc. (Nasdaq:PSTX) rallied strongly on Wednesday following the announcement, with traders pushing shares of the small cap up to $3.00/share (+23.97%) at the session high. This move is a strong continuation of the success this stock found during the back half of April.

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet delivery technology. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

View the original article on AllPennyStocks.com

]]>

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire